ArticleCancer cell international2026
TMEM70 drives breast cancer progression via mitochondrial oxidative phosphorylation and microenvironment remodeling.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- miR-489 induces immunogenic cell death in breast cancer by targeting LAPTM4B.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTMEM70 is a nuclear-encoded inner mitochondrial membrane protein involved in ATP synthase assembly and oxidative phosphorylation (OXPHOS). Although previous studies have linked TMEM70 to breast cancer prognosis and copy number alteration, its biological role in breast cancer remains incompletely defined.
methodsWe integrated bulk transcriptomic, proteomic, clinical, spatial transcriptomic, and single-cell RNA-sequencing data to characterize TMEM70 expression, prognostic relevance, spatial distribution, immune context, intercellular communication, and pathway associations in breast cancer. Gain- and loss-of-function assays were performed to evaluate proliferation, migration, apoptosis, and mitochondrial function. Pharmacogenomic analysis, Connectivity Map screening, and molecular docking were used to identify candidate compounds associated with the TMEM70-high state.
resultsTMEM70 was consistently upregulated in breast cancer across datasets and platforms and was associated with poor prognosis. Spatial and single-cell analyses showed that TMEM70 was enriched in malignant regions and malignant cell populations. High TMEM70 expression was also associated with an immune-active but functionally constrained microenvironment, characterized by altered immune-cell correlations, cancer-immunity-cycle activity, immunoregulatory remodeling, and enhanced MIF-centered intercellular communication. Functionally, TMEM70 promoted proliferation and migration while suppressing apoptosis in breast cancer cells. Mechanistically, TMEM70 was closely associated with mitochondrial OXPHOS and maintained mitochondrial membrane potential, redox homeostasis, ATP production, and OXPHOS-related protein expression. Entinostat and clofibrate emerged as candidate compounds associated with the TMEM70-high program.
conclusionsTMEM70 is a clinically relevant pro-tumor factor in breast cancer and may promote malignant progression, at least in part, by sustaining mitochondrial OXPHOS and supporting a tumor-favoring microenvironment. TMEM70 may therefore serve as a promising biomarker and potential therapeutic target in breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.